evipedia.ai
← Back

Monolaurin for Health & Longevity

Evidence Review created on 10/21/2026 using AI4L / Opus 5.5

Also known as: Glycerol Monolaurate, GML, Glyceryl Monolaurate, Glycerin Monolaurate, Glyceryl Laurate, Glycerol Monododecanoate, 1-Monolaurin, Lauric Acid Monoglyceride, Monolauroylglycerol, Lauricidin

Motivation

Monolaurin is a fat-like compound made by joining lauric acid, the main fatty acid of coconut oil, to glycerol, the backbone of ordinary dietary fats. Small amounts occur naturally in coconut oil and human breast milk, and the food and cosmetics industries use it widely as a blending agent and preservative. As an oral supplement, it is promoted for immune support and for keeping unwanted microbes in check. Its main proposed action is to break open the fatty outer coats of certain bacteria, yeasts and viruses.

Interest grew from decades of laboratory work testing monolaurin against bacteria, yeasts and viruses, and from its trial use in experimental vaginal and nasal gels. People focused on long-term health have adopted it in protocols aimed at recurrent infections and gut balance, often at gram-level daily amounts.

This review examines what human, animal and laboratory studies show about monolaurin’s benefits and risks, how it is used in practice, and how strong the evidence is for people seeking to protect long-term health.

Benefits - Risks - Protocol - Conclusion

This section lists overview sources that discuss monolaurin, its antimicrobial lipid class, or its use in clinical practice.

Only three items are listed because few sources discuss monolaurin itself in depth; the rest of the literature is laboratory research or product marketing. No monolaurin content was found from Peter Attia, Andrew Huberman, Life Extension Magazine or Lifespan.io. Rhonda Patrick mentions monolaurate only briefly in a members-only Q&A, distinguishing it from lauric acid, and Chris Kresser mentions it only in passing within broader yeast-treatment discussions; both are too brief to list.

Grokipedia

  • Monolaurin

    An AI-written encyclopedia entry covering monolaurin’s chemistry, natural occurrence, production methods and laboratory antimicrobial activity; useful background, though it mostly summarizes laboratory findings.

Examine

No Examine article on monolaurin exists.

ConsumerLab

Systematic Reviews

No systematic reviews or meta-analyses for Monolaurin were found on PubMed as of 10/20/2026. Neither the claimed antimicrobial benefits nor the principal risks of monolaurin are represented by a systematic review.

Mechanism of Action

Monolaurin, also called glycerol monolaurate (GML), is a monoglyceride: one lauric acid chain attached to glycerol. It acts like a mild detergent inserting into fatty membranes (Yoon et al., 2018).

  • Microbial membranes: In culture GML disintegrates enveloped viruses (viruses with a fatty coat) (Hierholzer & Kabara, 1982), inhibits Gram-positive bacteria (bacteria with a thick single-layer wall, such as Staphylococcus aureus) (Kabara et al., 1972; Kabara later developed the Lauricidin supplement) and kills Candida yeasts (Strandberg et al., 2010, co-authored by Marnie Peterson of GML developer Hennepin Life Sciences).
  • Toxin suppression: At sub-lethal levels GML blocks bacterial signal transduction (internal messaging that switches on toxin genes), reducing toxic shock syndrome toxin-1 (TSST-1, cause of a life-threatening toxin illness) output (Projan et al., 1994, led from the company Applied Microbiology, Inc.); lauric acid released by bacterial enzymes acts equally (Ruzin & Novick, 2000).
  • Host immune cells: GML reorders lipids in human T cell membranes and reduces T cell receptor (the cell’s antigen sensor) signaling and cytokine (immune signaling protein) release (Zhang et al., 2016).
  • Competing view: Human serum albumin (the main blood protein) binds GML and largely reverses that suppression (Zhang & Houtman, 2016), and lipases (fat-splitting enzymes) digest dietary monoglycerides, so whether oral doses reach active concentrations outside the gut is unknown.

Pharmacology: No human pharmacokinetic (absorption and clearance) study exists; half-life and tissue distribution are unknown. Adult serum holds about 0.5 µg/mL (Sola et al., 2025). Selectivity is low. Metabolism is splitting by lipases, not cytochrome P450 (CYP, liver drug-metabolizing) enzymes.

Historical Context & Evolution

Monolaurin’s original uses were industrial: food blending agent, preservative and cosmetic ingredient. Mono- and diglycerides, including lauric esters, are affirmed by the U.S. Food and Drug Administration (FDA) as GRAS (generally recognized as safe) food ingredients (21 CFR 184.1505).

  • 1970s–1980s: Jon Kabara screened 30 fatty acids and derivatives, finding lauric acid the most inhibitory saturated fatty acid against Gram-positive bacteria and monoglycerides the only esters that kept activity (Kabara et al., 1972); later work showed it inactivated enveloped viruses in culture (Hierholzer & Kabara, 1982). Kabara developed Lauricidin, the leading brand, a commercial interest in the early literature.
  • 1990s–2000s: Patrick Schlievert’s group found in the laboratory that GML curbs toxic shock toxins (Schlievert et al., 1992), then tested it as a vaginal gel that protected macaques from SIV (simian immunodeficiency virus, the monkey form of HIV, human immunodeficiency virus) (Li et al., 2009). Co-investigator Marnie Peterson is affiliated with Hennepin Life Sciences, which develops GML products (Schlievert & Peterson, 2020).
  • 2010s–2020s: Small human gel trials followed; a placebo-controlled trial for bacterial vaginosis (overgrowth of mixed vaginal bacteria) found no added cure (Mancuso et al., 2020). Laboratory work showed GML also dampens human immune cells (Zhang et al., 2016).

Health-optimization interest grew from coconut-oil enthusiasm and hope for a non-antibiotic antimicrobial. What changed is not a refutation of laboratory data but new, mixed human trials and a 2025 cohort linking blood monolaurin to fewer COVID-19 (coronavirus disease 2019) infections (Sola et al., 2025). No study has addressed aging.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: no human trial of monolaurin has improved a clinical endpoint, and oral monolaurin has never been tested against placebo for any clinical outcome.

Medium 🟩 🟩

No benefit reaches Medium: the controlled human studies measured microbial counts or toxin levels, or the body’s own monolaurin levels, rather than clinical outcomes of supplementation.

Low 🟩

Topical Suppression of Staphylococcus aureus Colonization and Toxins

Applied locally, GML reduced S. aureus toxins and counts. In a randomized study of 225 women, GML tampons held less toxin and interleukin-8 (IL-8, an inflammatory signal) (Strandberg et al., 2009); an uncontrolled nasal gel cut counts (Schlievert & Peterson, 2020). One group; infections unmeasured.

Magnitude: About a 3-log (roughly 1,000-fold) reduction in nasal S. aureus counts after 3 days of 5% GML gel, persisting 2–3 days (no control group) (Schlievert & Peterson, 2020).

Vaginal Yeast and Bacterial Vaginosis ⚠️ Conflicted

In a 36-woman randomized trial, 5% GML gel lowered Candida and Gardnerella vaginalis counts, sparing protective lactobacilli (Strandberg et al., 2010). A 109-woman placebo-controlled trial found no better cure of bacterial vaginosis (Mancuso et al., 2020). Net: microbial shifts did not yield clinical cure.

Magnitude: Clinical cure (all four Amsel criteria, the standard diagnostic signs, resolved) 8 percentage points lower with 5% monolaurin gel than with placebo gel (risk difference −0.08, 95% confidence interval [CI, range likely to contain the true value] −0.26 to 0.08; 17% vs 25%) (NCT02709005 posted results); p = 0.42 (p, the probability of a difference this large arising by chance; not significant) (Mancuso et al., 2020).

Lower Risk of COVID-19 Infection

Among 1,000 Italian healthcare workers, higher serum monolaurin predicted fewer SARS-CoV-2 (the COVID-19 virus) infections over six months (Sola et al., 2025). Indirect: it measured the body’s own levels, not supplementation. The full text’s 3-month group means do not match the abstract’s direction.

Magnitude: Hazard ratio (HR, relative rate of infection over time) 0.33 (95% CI 0.15–0.72) at 3 months and 0.39 (95% CI 0.17–0.93) at 6 months for serum levels above vs below 0.45 µg/mL; event rates by group were not reported (Sola et al., 2025).

Clearance of Oral Helicobacter pylori

A randomized study in China tested a mouthwash combining lysine with 0.2% GML against oral H. pylori and found higher clearance than stomach-directed therapy alone (Wang et al., 2014). Indirect: GML was tested only together with lysine, as a rinse.

Magnitude: Oral H. pylori cleared in 72.58% with the mouthwash vs 10.67% with standard gastric eradication therapy; gastric eradication 82.26% when oral infection was also treated vs 61.33% without (not compared between groups) (Wang et al., 2014).

Persistent Lyme Disease Symptoms

Seventeen volunteers with persistent Lyme disease took a blend of baicalein, luteolin, rosmarinic acid, monolaurin, cis-2-decenoic acid and iodine for six months; most reported feeling better (Goc et al., 2020). Uncontrolled, combination-only, and from an institute linked to a micronutrient vendor.

Magnitude: 67.4% reported a positive response and 17.7% slight improvement (no control group) (Goc et al., 2020).

Antiviral Activity Against Enveloped Viruses

GML inhibited HIV-1, yellow fever, mumps and Zika viruses in culture (Welch et al., 2020) and protected macaques from SIV (Li et al., 2009). The only human oral study, an uncontrolled 15-patient HIV pilot run with the drug company United Laboratories (Tayag et al., 2000), found small viral-load falls.

Magnitude: Mean viral load fell 0.13–0.40 log units after 6 months across the three arms, including a coconut-oil arm, short of the 2-log treatment target; it fell in 4 of 5 low-dose and 3 of 5 high-dose monolaurin patients (no control group) (Tayag et al., 2000).

Speculative 🟨

Protection Against Drug-Resistant and Invasive Staphylococcus aureus Infection

Monolaurin inhibited antibiotic-resistant S. aureus from eczema patients in laboratory assays (Laowansiri et al., 2025) and, given orally, improved survival in infected mice (Manohar et al., 2013). Basis is laboratory and animal only.

Gut Microbiota and Metabolic Health ⚠️ Conflicted

High-dose GML improved weight, lipids and glucose in high-fat-fed mice (Zhao et al., 2020). Low doses worsened them on a low-fat diet (Jiang et al., 2018). Net: direction depends on dose and diet.

Protection Against Intestinal Inflammation

Pretreatment with GML eased chemically induced colitis (bowel inflammation) in mice and raised Bifidobacterium and short-chain fatty acids (beneficial gut-bacteria products) (Mo et al., 2021). Basis is animal only; no human bowel-disease data exist.

Benefit-Modifying Factors

  • Genetic polymorphisms: No gene variant has been studied for monolaurin response. Because it acts on microbial membranes and is cleared by digestive lipases rather than CYP enzymes, common gene variants that alter drug handling are not expected to matter.
  • Baseline colonization and biomarkers: Benefit depends on a target being present: S. aureus nasal carriage, vaginal Candida or Gardnerella, or oral H. pylori. In the COVID-19 cohort, people already above 0.45 µg/mL serum monolaurin fared better (Sola et al., 2025).
  • Sex: Vaginal data apply only to women; the COVID-19 cohort was 70.5% female and found no sex effect (Sola et al., 2025). No sex-based differences for oral use are known.
  • Pre-existing conditions: People with eczema colonized by resistant S. aureus, recurrent vaginal infections or persistent gut complaints are the groups in whom topical or oral use has been explored.
  • Age: Human studies enrolled mainly younger and middle-aged adults (18–50 years in the vaginal-gel trial (Mancuso et al., 2020)). No data address older adults, whose weaker immune responses could make microbe-directed support more relevant, or less effective.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: human harm data come from single small trials of topical gels, and no controlled oral monolaurin trial has recorded adverse events.

Medium 🟥 🟥

No risk reaches Medium: the one controlled human signal, excess burning with vaginal gel, was not statistically tested and the trial’s main safety comparison was not significant; the remaining signals rest on an uncontrolled pilot, indirect food-fat data or animal work.

Low 🟥

Local Genital Irritation ⚠️ Conflicted

Vaginal monolaurin gel caused burning in 30 of 72 women vs 4 of 37 on placebo gel (NCT02709005 posted results), yet total urogenital symptoms did not differ significantly (Mancuso et al., 2020); a 36-woman trial reported no adverse events (Strandberg et al., 2010). Net: added burning is likely but unconfirmed.

Magnitude: Solicited urogenital adverse events 14 percentage points more common with monolaurin gel than placebo gel (risk difference 0.14, 95% CI −0.06 to 0.33; 50 of 71 vs 21 of 37 women) (NCT02709005 posted results); the published paper reports no significant difference, p = 0.24 (Mancuso et al., 2020).

Higher Low-Density Lipoprotein Cholesterol and Triglycerides

Digestion releases lauric acid, a saturated fat that raises LDL cholesterol (low-density lipoprotein, the main cholesterol carrier linked to artery disease) in coconut-oil trials (Neelakantan et al., 2020), indirect evidence. An uncontrolled oral pilot saw triglycerides exceed normal and LDL rise, within normal, at high dose (Tayag et al., 2000).

Magnitude: Coconut oil raised LDL by 10.47 mg/dL (95% CI 3.01–17.94) and HDL (high-density lipoprotein, the “protective” carrier) by 4.00 mg/dL (95% CI 2.26–5.73) vs nontropical vegetable oils (indirect: coconut oil, not monolaurin) (Neelakantan et al., 2020).

Digestive Upset and “Die-Off” Reactions

An uncontrolled 15-patient oral HIV pilot listed abdominal fullness and irregular bowel movements in its high-dose monolaurin arm (Tayag et al., 2000). The manufacturer advises starting low to limit “die-off” reactions (symptoms blamed on dying microbes) (Lauricidin). A 2019 review found no peer-reviewed oral supplementation trial (Barker et al., 2019).

Magnitude: Not quantified in available studies. The only human report is an uncontrolled pilot with no control group that lists these symptoms by arm without counts or rates (Tayag et al., 2000).

Speculative 🟨

Suppression of Immune Cell Activation ⚠️ Conflicted

In culture, GML dampens human T cell and B cell (antibody-producing cell) activation (Fosdick et al., 2022), but albumin largely reverses this (Zhang & Houtman, 2016). Net: relevance in blood is doubtful.

Increased Genital Herpes Susceptibility With Vaginal Use

A single vaginal dose of 5% GML markedly increased herpes simplex virus type 2 infection in mice (Moench et al., 2010). Basis is animal only; no human data exist.

Weight Gain and Gut Imbalance at Low Doses ⚠️ Conflicted

Low-dose GML raised body fat, LDL and inflammation in low-fat-fed mice (Jiang et al., 2018); four months of higher doses caused only modest weight gain (Mo et al., 2019). Net: unresolved, animal only.

Allergic Reactions in Coconut- or Palm-Sensitive People

Lauric acid for monolaurin comes from coconut or palm kernel oil, so trace proteins could theoretically trigger reactions. Basis is mechanistic only; no monolaurin-specific case reports were found.

Risk-Modifying Factors

  • Genetic polymorphisms: No variant affects monolaurin handling. Carriers of familial hypercholesterolemia (an inherited form of very high LDL cholesterol) variants (LDLR, APOB, PCSK9; genes controlling LDL clearance) may be more sensitive to added saturated fat.
  • Baseline LDL cholesterol: An already elevated LDL makes any lauric-acid-driven rise more consequential, especially at multi-gram daily intakes.
  • Sex: Genital irritation and herpes-susceptibility signals concern vaginal products in women; no sex differences in oral side effects are reported.
  • Pre-existing conditions: Immunosuppression, coconut or palm allergy, recurrent genital herpes (for vaginal use) and digestive disorders raise theoretical risk.
  • Age: Older adults more often take immunosuppressants or narrow-margin drugs (small gap between effective and toxic dose), raising interaction exposure; no age-specific safety data exist.

Key Interactions & Contraindications

No human interaction or pharmacokinetic study of monolaurin exists, so every interaction below is inferred.

  • Oral antibiotics (amoxicillin, cefalexin; fluoroquinolones, a broad-spectrum antibiotic class, such as ciprofloxacin): Monitor (theoretical). Monolaurin pretreatment raised marbofloxacin exposure in chickens (Tukra et al., 2024); consequence: altered antibiotic levels. Spacing doses 2 hours apart is a common precaution.
  • Immunosuppressants (tacrolimus, cyclosporine, mycophenolate): Avoid (theoretical). Laboratory T cell suppression could add to drug effects; consequence: higher infection risk. Use is typically coordinated with the prescribing team.
  • Lipid-lowering drugs (atorvastatin, rosuvastatin, ezetimibe): Monitor (theoretical). Lauric acid may partly offset LDL lowering; consequence: reduced lipid control. A lipid panel 8–12 weeks after starting detects this.
  • Narrow-margin oral drugs (levothyroxine, warfarin, digoxin): Monitor (theoretical). As a surfactant (detergent-like compound), monolaurin could change absorption; consequence: under- or over-dosing. Spacing by 2–4 hours and checking thyroid-stimulating hormone (TSH) or INR (international normalized ratio, a clotting test) after starting are common precautions.
  • Orlistat (over-the-counter Alli; a lipase blocker): Caution (theoretical). It blocks the enzymes that digest monolaurin; consequence: more unabsorbed fat and oily stools. The combination is generally avoided.
  • Over-the-counter vaginal antifungals and glycol-based lubricants (miconazole, clotrimazole, warming gels): Caution (theoretical). Glycol vehicles used in GML gels raised herpes susceptibility in mice (Moench et al., 2010); consequence: irritation. Layering products is generally avoided.
  • Antimicrobial supplements (oregano oil, caprylic acid, undecylenic acid, berberine): Monitor (theoretical). Additive antimicrobial and digestive effects; consequence: stomach upset or “die-off” symptoms. Introducing one at a time helps attribute side effects.
  • Coconut oil and medium-chain triglyceride (MCT) oil: Monitor (theoretical). Additive saturated-fat and lauric acid load; consequence: further LDL rise. All sources add to the same lipid effect.
  • L-lysine and probiotics: No interaction expected; consequence: none known. Lysine and GML were combined in the tested rinse (Wang et al., 2014); GML spared vaginal lactobacilli (Strandberg et al., 2010).
  • Vaccination: Monitor (theoretical). Laboratory T cell suppression could blunt responses; consequence: weaker immunity after vaccination. Pausing for a few days around vaccination is a precaution without data.

Populations who should avoid Monolaurin:

  • Pregnant or breastfeeding women at supplemental doses, because safety data are insufficient (RxList); the vaginal-gel trial excluded them (Mancuso et al., 2020)
  • People with known allergy to coconut or palm kernel products (theoretical)
  • Organ-transplant recipients and others on immunosuppressive therapy (theoretical)
  • People with recurrent genital herpes, for vaginal GML products (theoretical; mouse data)

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Low start with slow titration: Starting with a few pellets (well under one scoop) and increasing every few days (Lauricidin) mitigates digestive upset and “die-off” reactions.
  • Dosing with meals: Taking each dose with food reduces the risk of stomach upset and reflux-like discomfort.
  • Lipid check: A lipid panel at baseline and 8–12 weeks, with dose reduction or stopping if LDL rises meaningfully above the personal baseline, mitigates the lauric-acid-driven LDL rise.
  • Allergy screen: Confirming the oil source with the maker, and avoiding use with known coconut or palm-kernel allergy, prevents allergic reactions.
  • Vaginal products and herpes: Avoiding intravaginal GML gels with a history of genital herpes mitigates the mouse-derived herpes-susceptibility signal.
  • Drug spacing: Separating monolaurin from narrow-margin drugs and antibiotics by 2–4 hours mitigates altered drug absorption.
  • Immunosuppression check: Coordinating any use with the prescriber of immunosuppressive drugs mitigates additive immune suppression.
  • Patch test for topicals: Applying a topical product to a small skin area for 24–48 hours first prevents widespread irritation.

Therapeutic Protocol

Timing, cycling, titration steps and other uncited parameters below reflect common practice.

  • Manufacturer protocol (Lauricidin): A few pellets in week one, building to the most common amount, one blue scoop per meal (Lauricidin), about 3 g (Kresser Institute). Popularized by Jon Kabara; the maker has a financial interest.
  • Functional-medicine protocol: One 3 g scoop three times daily (9 g/day) in SIBO (small intestinal bacterial overgrowth) protocols discussed by Kresser Institute practitioner Tracey O’Shea (Kresser Institute).
  • Capsule products: Capsules supply 300 or 600 mg; matching 9 g/day needs 15–30 capsules (Kresser Institute).
  • Topical research regimens: 5% GML gel swabbed into the nostrils for 3 days (Schlievert & Peterson, 2020); 5% vaginal gel twice daily for 3 days (Mancuso et al., 2020).
  • Conventional alternatives: For the same targets, standard care uses prescription agents (mupirocin for nasal S. aureus, metronidazole for bacterial vaginosis, antivirals for herpes); monolaurin is used alongside or instead of these, without head-to-head data.
  • Time of day: Doses are taken with meals, morning to evening; no timing study exists.
  • Half-life: Unknown; no human pharmacokinetic study exists, and digestive lipases split monolaurin into lauric acid and glycerol.
  • Single vs split dosing: Split into 2–3 doses daily, as the manufacturer advises (Lauricidin).
  • Genetic polymorphisms: No data on gene variants and response; CYP variants are irrelevant. People with familial hypercholesterolemia variants favor lower doses.
  • Sex: No sex-based dosing differences are known; vaginal regimens apply to women only.
  • Age: Older adults typically start at the low end, with a review of medications, especially immunosuppressants and narrow-margin drugs.
  • Baseline biomarkers: A baseline LDL guides the ceiling dose; documented colonization (nasal or vaginal culture) helps judge response.
  • Pre-existing conditions: Immunosuppression, coconut or palm allergy and recurrent genital herpes (vaginal use) argue against use; digestive sensitivity favors slower titration.

Discontinuation & Cycling

  • Short-term vs lifelong: Practitioners use monolaurin in courses of weeks, often during infection seasons or gut protocols; continuous long-term use has never been studied.
  • Withdrawal effects: None reported; monolaurin has no known dependence or rebound mechanism.
  • Tapering: Not required; stopping abruptly carries no known risk.
  • Cycling: No study tests cycling. Course-based use with breaks is common practice, partly to limit theoretical effects on immune cells and gut microbes.

Sourcing and Quality

  • Formulation: Available as mini-pellets (Lauricidin), capsules (typically 300–600 mg) and powders; pellets allow fine dose steps without fillers.
  • What to look for: Labels naming “glycerol monolaurate” or “monolaurin” as the sole active ingredient, with stated content per serving; coconut oil and lauric acid are not substitutes.
  • Third-party testing: Few monolaurin products carry United States Pharmacopeia (USP) or NSF International seals; a certificate of analysis confirming identity, monolaurin content and absence of solvents and heavy metals is the main quality check.
  • Brands: Lauricidin (Med-Chem Labs, developed by Jon Kabara) is the reference brand in practitioner protocols; capsule products are sold through practitioner channels such as Emerson Ecologics and Fullscript.
  • Source oil: Lauric acid is derived from coconut or palm kernel oil; the source matters for people with allergies or sustainability concerns.
  • Topical products: The research gels (5% GML in glycol-based vehicles) are not sold commercially; over-the-counter monolaurin creams are untested for most uses.

Practical Considerations

  • Time to effect: Topical gels reduced nasal S. aureus within 3 days (Schlievert & Peterson, 2020). For oral use, the only human study, an HIV pilot, saw viral-load falls at 6 months but not at 3 (Tayag et al., 2000).
  • Common pitfalls: Assuming coconut oil delivers monolaurin’s effect (coconut oils failed where monolaurin worked in mice (Manohar et al., 2013)); titrating too fast; underdosing with small capsules; expecting systemic antiviral protection.
  • Regulatory status: In the U.S., monolaurin-type mono- and diglycerides are GRAS food ingredients (21 CFR 184.1505); supplements may not claim to treat disease, and the FDA warned a seller in 2020 over COVID-19 claims (FDA warning letter).
  • Cost and access: Widely available without prescription; at practitioner doses of several grams daily, monthly cost exceeds that of typical single-ingredient supplements, but it is not exceptionally expensive.

Interaction with Foundational Habits

  • Sleep: No interaction (none known). No study has examined sleep; monolaurin has no known effect on sleep-regulating hormones or brain chemistry, and evening doses taken with dinner are common.
  • Nutrition: Potentiating and blunting, depending on context. Taken with meals for tolerance; fat and starch in foods reduced its antibacterial activity in food tests (Zhang et al., 2009). Its lauric acid adds to dietary saturated fat, as does coconut oil.
  • Exercise: No interaction (none known). No study has tested monolaurin with training; there is no known effect on muscle growth, endurance or recovery, and no timing relative to workouts is needed.
  • Stress management: Indirect (theoretical). No study has measured monolaurin’s effect on cortisol; laboratory dampening of T cell cytokines suggests no added immune stimulation during stressful periods, contrary to “immune-boosting” marketing.

Monitoring Protocol & Defining Success

Before starting, a baseline lipid panel is the main safety test, because monolaurin is digested to lauric acid, a saturated fat that raises LDL cholesterol. A complete blood count with differential is a reasonable baseline for people with immune conditions, given laboratory evidence that monolaurin can dampen immune cells. Where a specific target is pursued, such as nasal S. aureus carriage or recurrent vaginal yeast, a baseline culture documents the starting point.

Ongoing monitoring follows this cadence: lipid panel at 8–12 weeks, then every 6–12 months during continued use; repeat cultures 1–4 weeks after a topical or oral course; complete blood count at 3 months and then yearly for people with immune conditions. Success is defined by fewer documented infections or symptom days compared with the individual’s own history, without an LDL rise.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
LDL cholesterol <100 mg/dL (NCEP ATP III “optimal” category) Safety check: lauric acid may raise it NCEP ATP III (National Cholesterol Education Program Adult Treatment Panel III) classification (NCEP, 2002); conventional reference range on most U.S. lab reports: <100 mg/dL desirable. Fasting not required for most panels; pair with HDL and triglycerides.
Absolute lymphocyte count 1.0–4.8 × 10⁹/L (standard reference range) Safety check: theoretical immune-cell suppression Part of a complete blood count with differential; no fasting needed; morning draws reduce daily variation. Relevant mainly for people with immune conditions.
Nasal or vaginal culture for the target microbe No established target; track change from the individual’s own baseline count Expected to change: colonization is expected to fall Swab before and 1–4 weeks after a course; same laboratory and method each time.

Qualitative markers:

  • Frequency and duration of colds, cold sores or other recurrent infections compared with the prior year
  • Digestive tolerance (bloating, loose stools, reflux) during titration
  • Vaginal or nasal symptoms when topical or targeted use is the goal
  • Energy and general well-being during and after a course

Emerging Research

  • Radiation dermatitis hydrogel trial: A 54-patient pilot RCT (randomized controlled trial) of a bacterial cellulose-monolaurin hydrogel vs placebo cream to prevent severe skin injury from breast radiotherapy (NCT05079763), recruiting, completion 2028. Positive: first clinical-endpoint benefit for topical monolaurin. Null: further weakens topical claims.
  • Monolaurin vs mupirocin ointment: A 40-participant pediatric randomized skin-infection trial in the Philippines (NCT06046937) completed July 2023; no results posted or published as of October 2026.
  • Congenital ichthyosis cream: A 90-patient phase III study of monolaurin cream for congenital ichthyosis (an inherited scaly-skin disorder) (NCT00004690) completed 1998; no results posted or published.
  • Petrolatum and analog formulations: GML in petrolatum killed resistant S. aureus and streptococci in laboratory tests and S. aureus in a rabbit dermatitis model (Schlievert et al., 2026); a sulfur-substituted analog showed antifungal, antibacterial and anti-inflammatory activity (Schlievert et al., 2025, led from its developer, Niche Biopharmaceuticals). Human trials would test these.
  • Serum monolaurin and infection risk: The COVID-19 cohort (Sola et al., 2025) needs replication and a supplementation trial; a null trial would leave blood levels as a marker of diet rather than a cause of protection.
  • Immune suppression in humans: Laboratory T and B cell suppression (Fosdick et al., 2022) has never been measured in people taking oral monolaurin; such data could weaken or strengthen the immune-support case.
  • Gut microbiota in humans: Conflicting mouse results (Zhao et al., 2020; Jiang et al., 2018) call for a controlled human microbiome and metabolic study at supplement doses.

Conclusion

Monolaurin is a natural fat-derived compound, made from the main fatty acid in coconut oil, that is widely used in foods and sold as a supplement for immune and gut support. For health-focused adults willing to follow structured protocols, the evidence is thinner than its popularity suggests.

Its strengths are real but narrow. In the laboratory and in animals it kills or disarms many bacteria, yeasts and fat-coated viruses. In people, gels applied in the nose or vagina reduced certain microbes, and tampons containing it reduced bacterial toxins, yet the one treatment trial that compared it with a placebo gel found no better cure rate. People with higher natural blood levels had fewer coronavirus infections in one large observational study, but this does not show that supplements produce that effect. No study has tested oral monolaurin for preventing infections, slowing aging or extending life.

Its risks appear low at food-like amounts, but gram-level daily use has never been systematically studied. Concerns include a possible rise in harmful cholesterol from the saturated fat it releases during digestion, laboratory signs that it can dampen immune cells, and animal data on genital herpes risk with vaginal use.

Much of the human and early laboratory research comes from investigators linked to companies that develop or sell monolaurin products, including the developer of the leading supplement brand. Overall, monolaurin is a plausible but largely unproven tool, with benefits so far shown mainly on direct contact rather than as an oral supplement.

Top - Benefits - Risks - Protocol